Form 4: Intensity Therapeutics Principal Accounting Officer Acquires Stock Options

John M. Wesolowski, Principal Accounting Officer of Intensity Therapeutics, Inc., acquired stock options for 100,000 shares of common stock on May 2, 2025.

Summary

• On May 2, 2025, John M. Wesolowski, the Principal Accounting Officer of Intensity Therapeutics, Inc., acquired options to purchase 100,000 shares of the company's common stock.
• The exercise price of these options is $0.57 per share.
• The options vest in five equal annual installments, starting on May 2, 2025, and expire on May 2, 2035.
• A power of attorney was executed on October 29, 2024, granting certain individuals the authority to file forms on behalf of John M. Wesolowski.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction (stock option grant) and suggests a positive alignment of interests between management and shareholders. It's a routine event, but generally viewed favorably.

Positives

• The acquisition of stock options by a key officer aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the officer.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize and retain key personnel. This grant aligns with standard compensation practices.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
• The vesting schedule of five years is also fairly standard, aligning with industry norms for long-term incentive plans.

Stakeholder Impact

• The stock option grant could have a slightly positive impact on shareholder sentiment as it aligns management's interests with the company's long-term success.
• The grant incentivizes the Principal Accounting Officer to contribute to the company's financial performance.

Key Dates

Keywords

stock options, Form 4, Intensity Therapeutics, Wesolowski, Principal Accounting Officer, beneficial ownership, securities, power of attorney